Edward Cliff, Haematology Registrar at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, shared a post on LinkedIn:
“Just out in Blood Journals Portfolio, led by fantastic heme/onc fellow Alex Ge, we assessed the global landscape of access to commercial CAR T-cells, and find that even among the G20 countries, less than half of the FDA-approved indications are funded.
Our findings have implications on both the policy and clinical sides: we must urgently figure out ways to manufacture CAR T more affordably and scalably to increase access to this life-saving therapy. And we must consider access when designing clinical trials and making guidelines that apply to patients across the world.”
Title: Global access to commercial CAR T cells: A cross-sectional study of health technology assessment in the G20
Authors: Alex Y Ge, William B Feldman, Martin F Kaiser, Kai Rejeski, Gloria Iacoboni, Gaurav Narula, Jason Yongsheng Chan, Michael Dickinson, Aaron S Kesselheim, Edward Robert Scheffer Cliff
Read the Full Article.
More posts featuring Edward Cliff.
